A CDC study found that approximately 27 million U.S. adults used GLP-1 medications in 2025, with nearly half reporting modified use—including skipped doses and reduced amounts—primarily due to cost and access barriers. Younger users were disproportionately affected, and those using compounded GLP-1 drugs showed particularly high rates of off-prescription usage.
Background
GLP-1 receptor agonists like semaglutide and tirzepatide have surged in popularity for diabetes and weight loss treatment, leading to supply shortages and a rise in compounded alternatives from unregulated sources.
- Source
- Ars Technica
- Published
- Nov 14, 2026 at 05:59 AM
- Score
- 6.0 / 10